UCB Pharma S Sample Clauses

UCB Pharma S. A., a limited liability corporation incorporated under the laws of Belgium, with registered office at Xxxxx xx xx Xxxxxxxxx 00, 0000 Xxxxxxxx, Xxxxxxx (“UCB”)
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
UCB Pharma S. A., a corporation incorporated under the laws of Belgium, having its registered offices at Alxxx xx xx Xxxxxxxxx 00, 0000 Xxxxxxxxx, Xxxxxxx, hereinafter referred to as “UCB PHARMA”, and AND DERMIRA, INC., a corporation organised under the laws of the State of Delaware, with its principal offices located at 2000 Xxxxxxxx Xxxx, Xxxxx 000, Xxxxxxx Xxxx, Xxxxxxxxxx 00000, the United States of America, hereafter referred to as “DERMIRA”; Individually a “Party” and together the “Parties”.
Sample 1Sample 2Sample 3
UCB Pharma S. A. Five Prime Therapeutics, Inc. By: /s/ Xxxxxx Xxxx By: /s/ Xxxxx X. Xxxxxxxx Name: Xxxxxx Xxxx Name: Xxxxx X. Xxxxxxxx Title: Executive VP, President Title: Chief Executive Officer UCB New Medicines UCB Pharma S.A. By: /s/ Xxxx Xxxxx Name: Xxxx Xxxxx Title: Executive VP & General Counsel *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Exhibit A Research Plan UCB and FivePrime are parties to a Research Collaboration and License Agreement, effective March 14, 2013 (the “Collaboration Agreement”), to which this Research Plan is attached as Exhibit A. Capitalized terms used in this Research Plan without definition shall have the respective meanings set forth in the Collaboration Agreement. To the extent that any of the terms or conditions in this Research Plan conflict with any of the terms or conditions set forth in the Collaboration Agreement, the terms of the Collaboration Agreement shall govern.
Sample 1Sample 2
UCB Pharma S. A. (“UCB”) is the assignee of the ‘117 Application and the ‘658 Application. [*] A hearing was held on January 29, 2010 regarding the first phase of the interference, which relates to substantive motions except those for priority of invention.
Sample 1
UCB Pharma S. A. By: /s/ Xxxx Xxxxxx Name: Xx. Xxxx Xxxxxx Title: BP, NewMedicines Therapeutics Five Prime Therapeutics, Inc. By: /s/ Xxxxx X. Xxxxxxxx Xxxxx X. Xxxxxxxx President and Chief Executive Officer UCB Pharma S.A. By: /s/ Xxx Xxxx Name: Xx. Xxx Xxxx Title: VP, Immunology Research CONFIDENTIAL Exhibit A Research Plan Addendum *** *** INDICATES ONE PAGE OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Sample 1
UCB Pharma S. A. Five Prime Therapeutics, Inc. By: /s/ Xxxx Xxxxxx By: /s/ Xxxxx X. Xxxxxxxx Name: Xxxx Xxxxxx Xxxxx X. Xxxxxxxx President and Chief Executive Officer Title: Vice President, New Medicines Therapeutics UCB Pharma S.A. By: /s/ Xxxxxx Xxxxxxxx Name: Xxxxxx Xxxxxxxx, Ph.D. Title: Director, Research Alliances & Strategy *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Exhibit D UCB Exempted Protein List ***
Sample 1
UCB Pharma S. P.A. By: (Signature) Name: XX. XXXXXXX XXXXXX (Name Printed) Title: Medical Director Date: By: (Signature) Name: DR.SSA XXXXXX XXXXXXXX specificazioni si intendono validi anche dopo la data di risoluzione o scadenza della Convenzione, fra cui, a titolo esemplificativo ma non esaustivo, gli obblighi contenuti nel Programma dello Studio e gli Articoli 15 (Informazioni confidenziali e non divulgabili), 16 (Pubblicazione e divulgazione di informazioni), 17 (Proprietà intellettuale), 21 (Leggi in vigore) e 23 (Validità) rimarranno in vigore anche dopo la cessazione o la scadenza del presente Accordo. VISTO QUANTO RIPORTATO SOPRA, i rappresentanti legali delle parti hanno apposto la propria firma a formalizzazione del presente Contratto La presente Convenzione viene rilasciata in tre copie originali, una copia per ciascuna delle PARTI PER UCB PHARMA S.P.A. (Firma) Nome: XX. XXXXXXX XXXXXX (Nome in Stampatello) Titolo: Direttore Medico Data: (Name Printed) Title: Human resources and finance Director Date: INSTITUTION PHYSICIAN By: By: (Signature) (Signature) (Firma) Nome: DR.SSA XXXXXX XXXXXXXX (Nome in Stampatello) Titolo: Direttore risorse umane e finance Data: PER L’AZIENDA OSPEDALIERA Per lo SPERIMENTATORE Name: Name: (Name Printed) (Name Printed) (Firma) (Firma) Title: Title: Nome: Nome: Date: Date: (Nome in stampatello) (Nome in stampatello) Titolo: Titolo: CRO Hippocrates Research S.r.l., By: (Signature) Name: Xx. XXXXXXX ENOTARPI Title: Legal Representative Date: Data: Per la CRO Hippocrates Research S.r.l. (Firma) Nome: Dott. DANIELE ENOTARPI Data: Titolo: Legale Rappresentante SCHEDULE 1: BUDGET AND PAYMENT SCHEDULE In Euros A. PAYMENT TERMS: Data: TABELLA 1: BUDGET E PROGRAMMA DEI PAGAMENTI In Euro CRO will reimburse INSTITUTION in Euros every six months. The amounts will be refunded upon receipt of the invoice to be paid in 60 days. Reimbursements will be calculated on a completed visit per Study subject that is enrolled into the Study (“Enrolled Subject”) basis in accordance with the attached Budget, unless otherwise noted in hereto. Each payment due will be made based upon prior quarterly enrollment data confirmed by Enrolled Subject CRFs filled in by the PHYSICIAN supporting Enrolled Subject visitation with no outstanding queries. CRFs will qualify for payment based on Enrolled Subject status as follows: • Visits completed per Observational Plan are fully payable; • Discontinued or lost to follow up are prorated for the number of completed visits; ...
Sample 1
AutoNDA by SimpleDocs

Related to UCB Pharma S

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Licensee Licensee represents and warrants that:

  • Joint Manufacturing Committee In accordance with Section 2.5(c)(iv), the Parties shall promptly establish and convene a joint Manufacturing Committee (the “JMC”) for the overall coordination and oversight of the Manufacturing of clinical and commercial supplies of the Product under this Agreement as provided in the Manufacturing Plan (including the Manufacture of API, Drug Product and Finished Product). The JMC shall consist of representatives of each Party, and shall operate by procedures, as set forth in Section 2.5. The role of the JMC shall be:

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Licensor any Person from whom a Grantor obtains the right to use any Intellectual Property. Lien: any Person’s interest in Property securing an obligation owed to, or a claim by, such Person, whether such interest is based on common law, statute or contract, including liens, security interests, pledges, hypothecations, statutory trusts, reservations, exceptions, encroachments, easements, rights-of-way, covenants, conditions, restrictions, leases, and other title exceptions and encumbrances affecting Property. Lien Waiver: an agreement, in form and substance satisfactory to Collateral Agent, by which (a) for any material Collateral located on leased premises, the lessor waives or subordinates any Lien it may have on the Collateral, and agrees to permit Collateral Agent to enter upon the premises and remove the Collateral or to use the premises to store or dispose of the Collateral; (b) for any Collateral held by a warehouseman, processor, shipper, customs broker or freight forwarder, such Person waives or subordinates any Lien it may have on the Collateral, agrees to hold any Documents in its possession relating to the Collateral as agent for Collateral Agent, and agrees to deliver the Collateral to Collateral Agent upon request; (c) for any Collateral held by a repairman, mechanic or bailee, such Person acknowledges Collateral Agent’s Lien, waives or subordinates any Lien it may have on the Collateral, and agrees to deliver the Collateral to Collateral Agent upon request; and (d) for any Collateral subject to a Licensor’s Intellectual Property rights, the Licensor grants to Collateral Agent the right, vis-à-vis such Licensor, to enforce Collateral Agent’s Liens with respect to the Collateral, including the right to dispose of it with the benefit of the Intellectual Property, whether or not a default exists under any applicable License.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Sublicensee The term “

  • Sublicensees Licensee shall have the full right (but not the obligation) to sublicense those rights granted to it under Section 2.1 to a Third Party (a “Sublicensee”); provided, however, that, prior to the payment of the first milestone pursuant to Section 7.2, Licensee may not grant any such sublicense to any contract research organization conducting Clinical Trials of Products or any Third Parties conducting contract Manufacturing activities without Licensee’s prior written notice (at least twenty (20) Business Days in advance) to Lilly, which shall include a description of the rights to be granted and the purpose therefor, the identity of the Third Party and the countries involved, and Lilly’s prior written consent, but such consent shall only be required (i) until such time as Licensee is the holder of record for the Regulatory Materials related to Taladegib and (ii) to the extent such organization is not performing services for Licensee as of the Effective Date; and provided further, that Licensee shall remain responsible for the performance by any of its Sublicensees. With respect to any Sublicensee granted a sublicense to any Commercialization rights hereunder, Licensee shall ensure that each of its Sublicensees accepts in writing all applicable terms and conditions of this Agreement, including the non-compete, reporting, audit, inspection and confidentiality provisions hereunder. Each Sublicensee shall also be prohibited from further sublicensing. For the avoidance of doubt, (a) Licensee will remain directly responsible for all amounts owed to Lilly under this Agreement, and (b) each Sublicensee is subject to the negative and restrictive covenants set forth in Sections 2.3.1 and 2.5, respectively. Licensee hereby expressly waives any requirement that Lilly exhaust any right, power or remedy, or proceed against a subcontractor, for any obligation or performance hereunder prior to proceeding directly against Licensee.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

Time is Money Join Law Insider Premium to draft better contracts faster.